医学
血小板
药效学
氯吡格雷
等位基因
药品
科克伦图书馆
内科学
荟萃分析
单核苷酸多态性
药理学
抗血小板药物
阿司匹林
生物信息学
基因型
药代动力学
生物
遗传学
基因
作者
Qian Xiang,Shuang Zhou,Joshua P. Lewis,Alan R. Shuldiner,Guanhua Ren,Yimin Chen
标识
DOI:10.2174/1381612823666170817122043
摘要
Background: Platelet endothelial aggregation receptor 1 (PEAR1) may affect platelet-platelet contact and aggregation. The aim of this study was to assess the association between PEAR1 polymorphisms and risks of platelet aggregation. Methods: We searched the PubMed, EmBase, and Cochrane Library electronic databases for articles published through November 30th. 2016. Meta-analysis was performed to examine the relationship between PEAR1 and platelet aggregation and sensitivity analysis by removing individual study from meta-analysis. We collected and analyzed the results of 5 trials involving 5466 patients. Results: Our results demonstrated that the G allele of rs12041331 was associated with a greater platelet aggregation by multiple agonists, both in the presence and absence of antiplatelet drugs, in several separate cohorts of different ethnicities along with an apparent allelic dose–response effect. However, the results of studies on rs2768759 locus were inconsistent and further studies are required. In the presence or absence of antiplatelet drugs treatment, the lowest platelet aggregation was observed in rs2768759 wild-type (AA) patients, followed by heterozygous (AC) and homozygous mutant (CC). Conclusion: PEAR1 rs12041331 is associated with platelet function and antiplatelet drug pharmacodynamics. Future studies on relationship between single nucleotide polymorphisms of PEAR1 and incidence of cardiovascular diseases are required. Keywords: Platelet aggregation, platelet endothelial aggregation receptor 1, single nucleotide polymorphism, meta-analysis, drugs, Metaanalysis.
科研通智能强力驱动
Strongly Powered by AbleSci AI